Inopak Ltd – FDA 483, Jul 20, 2018
An FDA inspection of Inopak Ltd, an OTC drug manufacturer, revealed significant deficiencies across its quality, laboratory, production, and equipment systems. The firm failed to thoroughly investigate microbial contamination in distributed products, lacked proper quality control oversight, and did not have essential written programs for annual product reviews, stability testing, process validation, equipment maintenance, and cleaning validation. Several observations, particularly regarding process validation, were repeat findings from previous inspections, indicating persistent non-compliance.
ID · b0d423fb-83ed-471d-844f-8b10236f68e6
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.